SINOVAC BIOTECH LTD

SVA · XNAS

CIK 1084201fmd_1V8YSGYPB4FAFSCW4W9AAWPE3TManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Dec 31, 2025, 17 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	72	174	230	246	511	19,365	1,473	470	361	386
Cost of revenue	22	20	25	32	67	989	658	147	141	124
Net investment income	–	–	–	–	–	0	0	248	–	–
Gross profit	50	154	205	214	443	18,376	815	323	221	262
Research and development	13	20	22	24	49	153	479	350	271	216
Selling, general and administrative	42	87	137	121	177	602	836	598	421	333
Total operating expenses	50	109	160	145	228	758	1,324	1,037	726	752
Operating income	1	45	45	69	216	17,618	(509)	(714)	(506)	(490)
Interest expense	2	2	1	1	1	3	1	5	6	10
Interest and investment income	1	1	2	2	2	103	157	87	29	33
Other non-operating income (expense)	0	0	0	1	0	(153)	297	559	528	209
Income before taxes	(0)	45	47	71	217	17,568	(48)	(84)	43	(262)
Income tax expense	3	8	10	6	31	3,448	11	36	2	(63)
Net income from continuing operations	(3)	37	36	65	185	14,120	(60)	(121)	41	(199)
Net income	(1)	26	22	45	110	8,122	14	(13)	41	(199)
Net income to common shareholders	(1)	26	22	40	104	8,122	14	(13)	91	(60)